Advertisement
UK markets open in 1 hour 35 minutes
  • NIKKEI 225

    38,052.77
    +424.29 (+1.13%)
     
  • HANG SENG

    17,615.88
    +331.34 (+1.92%)
     
  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     
  • GOLD FUTURES

    2,348.30
    +5.80 (+0.25%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,394.18
    +96.11 (+0.19%)
     
  • CMC Crypto 200

    1,385.37
    +2.80 (+0.20%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Guardant Health (GH) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Guardant Health (GH) closed at $81.80, marking a -1.21% move from the previous day. This change lagged the S&P 500's 0.16% loss on the day. Meanwhile, the Dow lost 0.43%, and the Nasdaq, a tech-heavy index, lost 0.14%.

Heading into today, shares of the provider of oncology testing services had gained 2.74% over the past month, outpacing the Medical sector's gain of 1.82% and lagging the S&P 500's gain of 3.63% in that time.

GH will be looking to display strength as it nears its next earnings release, which is expected to be February 24, 2020. On that day, GH is projected to report earnings of -$0.30 per share, which would represent no growth from the year-ago period. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $54.50 million, up 65.79% from the year-ago period.

Investors should also note any recent changes to analyst estimates for GH. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

ADVERTISEMENT

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 3.82% higher. GH is currently a Zacks Rank #1 (Strong Buy).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 72, which puts it in the top 29% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research